PMID- 26873487
OWN - NLM
STAT- MEDLINE
DCOM- 20170221
LR  - 20181113
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 37
IP  - 8
DP  - 2016 Aug
TI  - Correlation of TGF-beta1 and oxidative stress in the blood of patients with 
      melanoma: a clue to understanding melanoma progression?
PG  - 10753-61
LID - 10.1007/s13277-016-4967-4 [doi]
AB  - TGF-beta1 and oxidative stress are involved in cancer progression, but in melanoma, 
      their role is still controversial. Our aim was to correlate plasma TGF-beta1 levels 
      and systemic oxidative stress biomarkers in patients with melanoma, with or 
      without disease metastasis, to understand their participation in melanoma 
      progression. Thirty patients were recruited for melanoma surveillance, together 
      with 30 healthy volunteers. Patients were divided into two groups: 
      Non-metastasis, comprising patients with tumor removal and no metastatic episode 
      for 3 years; and Metastasis, comprising patients with a metastatic episode. The 
      plasmatic cytokines TGF-beta1, IL-1 beta, and TNF-alpha were analyzed by ELISA. For 
      oxidative stress, the following assays were performed: malondialdehyde (MDA), 
      advanced oxidation protein products (AOPP) levels, total radical-trapping 
      antioxidant parameter (TRAP) and thiol in plasma, and lipid peroxidation, SOD and 
      catalase activity and GSH in erythrocytes. Patients with a metastatic episode had 
      less circulating TGF-beta1 and increased TRAP, thiol, AOPP and lipid peroxidation 
      levels. MDA was increased in both melanoma groups, while catalase, GSH, and IL-1beta 
      was decreased in Non-metastasis patients. Significant negative correlations were 
      observed between TGF-beta1 levels and systemic MDA, and TGF-beta1 levels and systemic 
      AOPP, while a positive correlation was observed between TGF-beta1 levels and 
      erythrocyte GSH. Lower levels of TGF-beta1 were related to increased oxidative 
      stress in Metastasis patients, reinforcing new evidence that in melanoma TGF-beta1 
      acts as a tumor suppressor, inhibiting tumor relapse. These findings provide new 
      knowledge concerning this cancer pathophysiology, extending the possibilities of 
      investigating new therapies based on this evidence.
FAU - Santos Bernardes, Sara
AU  - Santos Bernardes S
AD  - Laboratory of Molecular Pathology, Londrina State University (UEL), Londrina, 
      Parana, Brazil.
FAU - de Souza-Neto, Fernando Pinheiro
AU  - de Souza-Neto FP
AD  - Laboratory of Molecular Pathology, Londrina State University (UEL), Londrina, 
      Parana, Brazil.
FAU - Pasqual Melo, Gabriella
AU  - Pasqual Melo G
AD  - Laboratory of Molecular Pathology, Londrina State University (UEL), Londrina, 
      Parana, Brazil.
FAU - Guarnier, Flavia Alessandra
AU  - Guarnier FA
AD  - Laboratory of the Pathophysiology of Muscle Adaptations, Londrina State 
      University (UEL), Londrina, Parana, Brazil.
FAU - Marinello, Poliana Camila
AU  - Marinello PC
AD  - Laboratory of Molecular Pathology, Londrina State University (UEL), Londrina, 
      Parana, Brazil.
FAU - Cecchini, Rubens
AU  - Cecchini R
AD  - Laboratory of Pathophysiology and Free Radicals, Londrina State University (UEL), 
      Londrina, Parana, Brazil.
FAU - Cecchini, Alessandra L
AU  - Cecchini AL
AD  - Laboratory of Molecular Pathology, Londrina State University (UEL), Londrina, 
      Parana, Brazil. alcecchini@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20160212
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
RN  - 0 (Advanced Oxidation Protein Products)
RN  - 0 (Antioxidants)
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Sulfhydryl Compounds)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - EC 1.11.1.6 (CAT protein, human)
RN  - EC 1.11.1.6 (Catalase)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - ULW86O013H (Glutathione Disulfide)
SB  - IM
MH  - Advanced Oxidation Protein Products/blood
MH  - Antioxidants/analysis
MH  - Biomarkers
MH  - Catalase/blood
MH  - Cytokines/blood
MH  - Disease Progression
MH  - Female
MH  - Glutathione Disulfide/blood
MH  - Humans
MH  - Lipid Peroxidation
MH  - Male
MH  - Malondialdehyde/blood
MH  - Melanoma/blood/*secondary
MH  - Middle Aged
MH  - Neoplasm Proteins/*blood/physiology
MH  - Oxidative Stress
MH  - Sulfhydryl Compounds/blood
MH  - Superoxide Dismutase/blood
MH  - Transforming Growth Factor beta1/*blood/physiology
OTO - NOTNLM
OT  - Malondialdehyde
OT  - Melanoma
OT  - Neoplasm recurrence
OT  - Oxidative stress
OT  - Transforming growth factor beta
EDAT- 2016/02/14 06:00
MHDA- 2017/02/22 06:00
CRDT- 2016/02/14 06:00
PHST- 2015/10/01 00:00 [received]
PHST- 2016/02/02 00:00 [accepted]
PHST- 2016/02/14 06:00 [entrez]
PHST- 2016/02/14 06:00 [pubmed]
PHST- 2017/02/22 06:00 [medline]
AID - 10.1007/s13277-016-4967-4 [pii]
AID - 10.1007/s13277-016-4967-4 [doi]
PST - ppublish
SO  - Tumour Biol. 2016 Aug;37(8):10753-61. doi: 10.1007/s13277-016-4967-4. Epub 2016 
      Feb 12.